Fundraising Fox
Oragenics
NYSE: OGENTampa, US · Florida corporation
Find your way into Oragenics
Sign up to see every warm intro you have to Oragenics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oragenics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.
Founders & leadership
AJ
Alan JoslynChief Executive Officer2016–2021Alan Joslyn has held executive leadership roles spanning over 2.5 years as CEO of Inimmune and prior experience at Lazarus Pharmaceuticals, where he focused on gastroenterology asset acquisition. His background includes expertise in navigating preclinical-to-clinical drug development transitions, corporate development in biotech, and capital markets strategy for both private and public companies.
MS
Michael SullivanExecutive
JH
Janet HuffmanChief Executive Officer & Chief Financial Officer
JP
James P. KellyChief Medical Officer
WP
William PeacockChief Clinical Officer
Board
RK
Robert KoskiBoard director
FT
Frederick TellingBoard director
AD
Alan DuntonBoard director
CP
Charles PopeBoard director
Reported raises · per SEC filings
Form D private placements$19.9M disclosed across 6 of 8 rounds · 2016–2026
▶$850KraisedAug 2023 · 2 investors · BiotechnologyRule 506(b)
▶$850KraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan DuntonDirector
- Frederick TellingDirector
- Kimberly MurphyExecutive Officer, Director
- Janet HuffmanExecutive Officer
- Charles PopeDirector
- Robert KoskiDirector
- Offering amount
- $850K
- Amount sold
- $850K
- Minimum investment
- $100K
- First sale
- Aug 2023
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$4.6MraisedMay 2020 · 1 investors · BiotechnologyRule 506(b)
▶$4.6MraisedMay 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PopeDirector
- Michael SullivanExecutive Officer
- Robert KoskiDirector
- Frederick TellingDirector
- Alan JoslynExecutive Officer, Director
- Alan DuntonDirector
- Amount sold
- $4.6M
- First sale
- May 2020
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$1.8MraisedApr 2018 · 2 investors · BiotechnologyRule 506(b)
▶$1.8MraisedApr 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan JoslynExecutive Officer, Director
- Frederick TellingDirector
- Charles PopeDirector
- Robert KoskiDirector
- Alan DuntonDirector
- Michael SullivanExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Sales commissions
- $144K
- Placement agents
- LADENBURG THALMANN & CO. INC.
- First sale
- Apr 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$6.7MraisedNov 2017 · 5 investors · BiotechnologyRule 506(b)
▶$6.7MraisedNov 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PopeDirector
- Michael SullivanExecutive Officer
- Frederick TellingDirector
- Robert KoskiDirector
- Alan DuntonDirector
- Alan JoslynExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- First sale
- Nov 2017
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$1.3MraisedMay 2017 · 3 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert KoskiDirector
- Frederick TellingDirector
- Alan DuntonDirector
- Charles PopeDirector
- Michael SullivanExecutive Officer
- Alan JoslynExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.3M
- First sale
- May 2017
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$4.7MraisedJul 2016 · 3 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJul 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frederick TellingDirector
- Alan DuntonDirector
- Alan JoslynExecutive Officer, Director
- Michael SullivanExecutive Officer
- Robert KoskiDirector
- Charles PopeDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Jun 2016
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies working in the same space as Oragenics.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $256.7K |
| National Science Foundation | Phase II | 2008 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $100K |
| National Science Foundation | Phase I | 2006 | $99.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Science Foundation | Phase I | 2004 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Oragenics do?
- Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.
- How much funding has Oragenics raised?
- Oragenics has disclosed $19.9M raised across 6 of its 8 known rounds.
- Where is Oragenics headquartered?
- Oragenics is headquartered in Tampa, US.